FDA approves Polatuzumab Vedotin Plus R-CHP for previously untreated DLBCL
This article originally appeared on OncLive. This version has been slightly modified. The FDA has approved polatuzumab vedotin-piiq (Polivy) plus rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone (R-CHP) for use in …